3CCH image
Deposition Date 2008-02-25
Release Date 2009-03-10
Last Version Date 2024-10-16
Entry Detail
PDB ID:
3CCH
Keywords:
Title:
H-2Db complex with murine gp100
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
(Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Free:
0.27
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:H-2 class I histocompatibility antigen, D-B alpha chain
Gene (Uniprot):H2-D1
Chain IDs:A, D, G, J
Chain Length:276
Number of Molecules:4
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Beta-2-microglobulin
Gene (Uniprot):B2m
Chain IDs:B, E, H, K
Chain Length:99
Number of Molecules:4
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:nonameric peptide murine gp100
Chain IDs:C, F, I, L
Chain Length:9
Number of Molecules:4
Biological Source:
Primary Citation
Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
Cancer Res. 69 7784 7792 (2009)
PMID: 19789338 DOI: 10.1158/0008-5472.CAN-09-1724

Abstact

Immunogenicity of tumor-associated antigens (TAA) is often weak because many TAA are autoantigens for which the T-cell repertoire is sculpted by tolerance mechanisms. Substitutions at main anchor positions to increase the complementarity between the peptide and the MHC class I (MHC-I) binding cleft constitute a common procedure to improve binding capacity and immunogenicity of TAA. However, such alterations are tailored for each MHC-I allele and may recruit different CTL specificities through conformational changes in the targeted peptides. Comparative analysis of substituted melanoma-differentiation antigen gp100 in complex with H-2D(b) revealed that combined introduction of glycine and proline residues at the nonanchor positions 2 and 3, respectively, resulted in an agonistic altered peptide with dramatically enhanced binding affinity, stability, and immunogenicity of this TAA. Peptide vaccination using the p2Gp3P-altered peptide version of gp100 induced high frequencies of melanoma-specific CTL in the endogenous CD8+ repertoire. Crystal structure analysis of MHC/peptide complexes revealed that the conformation of the modified p2Gp3P-peptide was similar to the wild-type peptide, and indicated that this mimotope was stabilized through interactions between peptide residue p3P and the tyrosine residue Y159 that is conserved among most known MHC-I molecules throughout mammalian species. Our results may provide an alternative approach to enhance MHC stabilization capacity and immunogenicity of low-affinity peptides for induction of robust tumor-specific CTL.

Legend

Protein

Chemical

Disease

Primary Citation of related structures